LI_183740
|
Pages: NA
|
Jun 2018 | 556 Views
|
![]() ![]() |
|
Author's :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
![]() ![]() ![]() |
![]() ![]() |
An insulin syringe aids in delivering insulin to diabetic patients in required doses. The insulin syringes consist of three parts-a needle, a barrel, and a plunger, and is available in various sizes. The size of the insulin syringe is selected based on the desired dosage of insulin to be administered to diabetic patients. The major factors that fuel the growth of the market are the rising aging population and increasing number of diabetic patients globally. In addition, increasing incidence of obesity and people adopting an unhealthy lifestyle supplement the market growth. However, high costs of advanced insulin syringes restrain the growth of the insulin syringe market.
The report segments the market on the basis of end users and region. Based on end user, the market is divided into hospital, homecare, and others. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players profiled in this market are Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, Biocon Ltd., Ypsomed AG, Wockhardt Ltd., Medtronic Plc, Abbott Laboratories, Animas Corporation, and F. Hoffmann-La Roche, Ltd.
Key Benefits
* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.
Enterprice
License/PDF
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high level data integrity, accurate analysis and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.